

REMARKS

The specification has been amended herein to include the continuing data on the first page.


New page 29 has been added to present the abstract of the invention in a manner according to USPTO guidelines. The abstract in the instant application is the same as the abstract in the corresponding International Application except that a typographical error in the first sentence of the abstract has been corrected in the instant application. Particularly, the word "to" has been added.

The sequence listing in the instant application corrects minor formatting errors that were in the International Application and adds the names of the inventors and continuing data, which were not in the International Application in conformity with US practice. Additionally, an initial computer readable form (CRF) of the sequence listing is submitted herewith. No new matter has been added.

Claims 1-4, 9-11, 13-21, 23 and 24 have been amended. Claims 1-4 were amended to incorporate the subject matter of claims 5-8. Claims 5-8 have been canceled. New claims 25-29 have been added. Thus upon entry of this amendment the pending claims are 1-4 and 9-29. The amendments have been made to better conform them to US practice and eliminate multiple dependencies.

No new matter has been added by way of this amendment. Therefore Applicants respectfully request that the instant amendment be entered and receive favorable consideration. The Examiner is invited to telephone the undersigned agent if any questions or concerns arise during examination.

Respectfully submitted,



Gregory W. Warren
Agent for Applicants
Registration No. 48,385
Telephone: 919-541-8646

Syngenta Biotechnology, Inc.
3054 Cornwallis Road
Research Triangle Park, NC 27709-2257
Date: 4/4/05